Pharmacokinetics of Pretargeted Monoclonal Antibody 2D12.5 and 88Y-Janus-2-(p-Nitrobenzyl)-1,4,7,10-tetraazacyclododecanetetraacetic Acid (DOTA) in BALB/c Mice with KHJJ Mouse Adenocarcinoma: A Model for 90Y Radioimmunotherapy

Cancer Research

Volumn 54, Issue 22, 1994, Pages 5937-5946

  Goodwin, David A ^a,b   Meares, Claude F ^c   Watanabe, Naoto ^a,b   McTigue, Maureen ^a,b   Chaovapong, Warak ^a,b   Ransone, Charles McK ^a,b   Renn, Oliver ^c   Greiner, Douglas P ^c   Kukis, David L ^c   Kronenberger, Sheila I ^a,b  

^a VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; GADOTERIC ACID; HAPTEN; INDIUM 111; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 2D 12 5; TRANSFERRIN; UNCLASSIFIED DRUG; YTTRIUM; YTTRIUM 90;

ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BINDING AFFINITY; BIOASSAY; BLOOD; BONE MARROW; BREAST ADENOCARCINOMA; CONTROLLED STUDY; DIFFUSION; DRUG DISTRIBUTION; DRUG HALF LIFE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INTRAVENOUS DRUG ADMINISTRATION; LIVER; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; RADIOIMMUNOTHERAPY;

ACETIC ACIDS; ANIMAL; ANTIBODIES, MONOCLONAL; HALF-LIFE; HETEROCYCLIC COMPOUNDS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; RADIOIMMUNOTHERAPY; SUPPORT, U.S. GOV'T, NON-P.H.S.; SUPPORT, U.S. GOV'T, P.H.S.; TISSUE DISTRIBUTION; YTTRIUM RADIOISOTOPES;

EID: 0028030105     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. McKeara, T. G., Radioimmunodetection of solid tumors. Cancer (Phila.), 71 (Suppl.): 4302-4313, 1993.
2. Press, O. W., Eary, J. F., Appelbaum, F. R., Martin, P. J., Badger, C. C., Nelp, W. B., Glenn, S., Butchko, G. Fisher, D., Porter, B. Matthews, D. C., Fisher, L. D., and Bernstein, I. D., Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N. Engl. J. Med. 329: 1219-1224, 1993.
3. Hnatowich, D. J., Griffin, T. W., Kosciuczyk, C., Childs, R. L., Mattis, J. A., Shealy, D., and Doherty, P. W., Pharmacokinetics of an 111 In-labelled antitumor antibody in cancer patients. J. Nucl. Med. 26: 849-858, 1985.
4. Chatal, J. F., Saccavini, J. C., Fumoleau, P., Douillard, J. Y., Curtet, C., Kremer, M. Le Mevel, B., and Koprowski, H., Immunoscintigraphy of colon carcinoma. J. Nucl. Med. 25: 307-314, 1984.
5. Wessels, B., and Rogus, R. D., Radionuclide selection and model absorbed dose calculations for radiolabeled tumor associated antibodies. Med. Phys. 11: 639-645, 1984.
6. Lee, Y.C.C. Washburn, L. C., Sun, T.T.H. Byrd, B. L., Crook, J. E., Hollloway, E. C., and Steplewski, Z., Radioimmunotherapy of human colorectal carcinoma xenografts using 90Y-labeled monoclonal antibody C017-1A prepared by two bifunctional chelate techniques. Cancer Res. 50: 4546-4551, 1990.
7. Moi, M. K., Meares, C. F., and DeNardo, S. J., The peptide way to macrocyclic bifunctional chelating agents: synthesis of 2-(p-nitrobenzyl)-1, 4, 7, 10-tetraazacyclododecane-N, N’.N.N-tetraacetic acid and the study of its yttrium(III) complex. J. Am. Chem. Soc. 110: 6266-67, 1988.
8. Renn, O., and Meares, C. F., Large-scale synthesis of the bifunctional chelating agent 2-(p-nitrobenzyl)-1, 4, 7, 10-tetraazacyclododecane-N, N, N’, N-tetraacetic acid, and the determination of its enantiomeric purity by chiral chromatography. Bioconjugate Chem. 3: 563-569, 1992.
9. Li, M., Meares, C. F., Zhong, G. R., Miers, L., Xiong, C. Y., and DeNardo, S. J., Labeling monoclonal antibodies with 90yttrium- and 111Indium-DOTA chelates: a simple and efficient method. Bioconjugate Chem. 5: 101-104, 1994.
10. Goodwin, D. A., Meares, C. F., McCall, M. J., McTigue, M., and Chaovapong, W., Pre-targeted immunoscintigraphy of murine tumors with indium-111 labeled bifunctional haptens. J. Nucl. Med. 29: 226-234, 1988.
11. Goodwin, D. A., Meares, C. F., McCall, M. J., Chaovapong, W., McTigue, M., and Diamanti, C. I., Pretargeted immunoscintigraphy with In-Ill, Ga-67 and Ga-68 labeled bivalent (“Janus”) haptens. J. Clin. Nucl. Med. 13: 9 Sp. 0, (Abstract A3), 1988.
12. Le Doussal, J. M., Martin, M., Gautherot, E. Delaage, M., and Barbet, J., In vitro and in vivo targeting of radiolabeled monovalent and divalent haptens with dual specificity monoclonal antibody conjugates: enhanced divalent hapten affinity for cell-bound antibody conjugate. J. Nucl. Med. 30: 1358-1366, 1989.
13. Karush, F., Multivalent binding and functional affinity. Contemp. Top. Mol. Immunol. 5: 217-228, 1976.
14. Goodwin, D. A., Meares, C. F., McTigue, M., Chaovapong, W. Diamanti, C. I., Ransone, C., and McCall, M. J., Pretargeted immunoscintigraphy: effect of hapten valency on murine tumor uptake. J. Nucl. Med. 33: 2006-2013, 1992.
15. Goodwin, D. A., Meares, C. F., Watanabe, N., McTigue, M. Chaovapong, W., Ransone, C. McN. Renn, O., and Greiner, D. P., Pretargeted Y-90 therapy: pharmacokinetics and therapeutic ratio in BALB/c mice with KHJJ mouse adenocarcinoma using mAb 2D12.5 and Y-88 Janus-DOTA. Clin. Nucl. Med. 18: 925 October 1993.
16. Thiers, R. C., Contamination in trace element analysis and its control. Methods Biochem. Anal. 5: 273, 1957.
17. McCall, M. J., Diril, H., and Meares, C. F., Simplified method for conjugating macrocyclic bifunctional chelating agents to antibodies via 2-iminothiolane. Bioconjugate Chem. 1: 222-226, 1990.
18. Traut, R. R., Bollen, A., Sun, T. T., Hershey, J.W.B. Sundberg, J., and Pierce, L. R., Methyl 4-mercaptobutyrimidate as a cleavable cross-linking reagent and its application to the Escherichia coli 30S ribosome. Biochemistry, 12: 3266-3273, 1973.
19. Penefsky, H. S., A centrifuged-column procedure for the measurement of ligand binding by beef heart F, Methods Enzymol. 56: 527-530, 1979.
20. Meares, C. F., McCall M.J. Reardon, D. T., Goodwin D.A. Diamanti C.I. and McTigue, M., Conjugation of antibodies with bifunctional chelating agents: isothiocyanate and bromoacetamide reagents, methods of analysis, and subsequent addition of metal ions. Anal. Biochem. 142: 68-78, 1984.
21. Reardon, D. T., Meares, C. F., Goodwin, D. A., McTigue, M., David, G. S., Stone, M. R., Leung, J. P., Bartholomew, R. M., and Frincke, J. R., Antibodies against metal chelates. Nature (Lond.), 316: 265-268, 1985.
22. Lowry, O. H., Roseborough, N. J., Farr, L., et al. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193: 265, 1951.
23. Goodwin, D. A., Sundberg, M. W., Diamanti, C. I., and Meares, C. F., 111-Indium radiopharmaceuticals in cancer localization. In: T.P. Haynie (ed.), 18th Annual Clinical Conference Monograph, Radiologic and Other Biophysical Methods in Tumor Diagnosis. M.D. Anderson Hospital and Tumor Institute, Houston, Texas, pp. 57-88, Yearbook Medical Publishers, 1975.
24. Gibaldi, M., and Perrier, D. (eds.). Pharmacokinetics, Ed. 2, pp. 445-449. New York: Marcel Dekker, Inc. 1982.
25. MIRD: Radionuclide data and decay schemes, p. 159. In: D.A. Weber, D. F., Eckerman, L. T., Dillman, J. C., Ryman (eds.), New York: Society of Nuclear Medicine, 1989.
26. Buras, R. B., Beatty, B. G., Williams, L. E., Wanek, P. M., Harris, J. B., Hill, R., and Beatty, J. D., Radioimmunotherapy of human colon cancer in nude mice. Arch. Surg. 125: 660-664, 1990.
27. Goodwin, D. A., Meares, C. F., David, G. F., McTigue, M., McCall, M. J., Frincke, J. M., Stone, M. R., Bartholomew, R. M., and Leung, J. P., Monoclonal antibodies as reversible equilibrium carriers of radiopharmaceuticals. Nucl. Med. Biol. 13: 383-391, 1986.
28. Goodwin, D., Meares, C. F., Diamanti, C. I., McCall, M. J., Lai, C., Torti, F. McTigue, M., and Martin, B., Use of specific antibody for rapid clearance of circulating blood background from radiolabeled tumor imaging proteins. Eur. J. Nucl. Med. 9: 209-215, 1984.
29. 2b constant domains. Mol. Immunol. 27; 181-190, 1990.
30. Anderson, L. D., Meyer, D. L., Battersby, T. R., Frincke, J. M., Mackensen, D., Lowe, S., and Conolly, P., Optimization of ligand structure for imaging with a bifunctional antibody. J. Nucl. Med. 29: 835, 1988.
31. Le Doussal, J. M., Grouaz-Guyon, A., Martin, M. Gautherot, E., Delaage, M., and Barbet, J., Targeting of indium 111-labeled bivalent hapten to human melanoma mediated by specific monoclonal antibody conjugates: imaging of tumors hosted in nude mice. Cancer Res. 50: 3445-3452, 1990.
32. Kosmos, C., Snook, D. Gooden, C. S., Courtenay-Luck, N. S., McCall, M. J., Meares, C. F., and Epenetos, A. A., Development of humoral immune responses against a macrocyclic chelating agent (DOTA) in cancer patients receiving radioimmunoconjugates for imaging and therapy. Cancer Res. 52: 904-911, 1992.
33. Watanabe, N., Goodwin, D. A., Meares, C. F., McTigue, M., Chaovapong, W. Ransone, C., McN. and Renn, O., Immunogenicity in rabbits and mice of an antibodychelate conjugate: comparison of (S) and (R) enantiomers, and an acyclic chelating agent. Cancer Res. 54: 1049-1054, 1994.
34. Johnson, D. A., Barton, R. L., Fix, D. V., Scott, W. O., and Gutowski, M. C., Induction of immunogenicity of monoclonal antibodies by conjugation with drugs. Cancer Res. 51: 5774-5776, 1991.
35. DeNardo, G. L., Kroger, L. A., DeNardo, S. J., Miers, L. A., Salako, Q., Kukis, D. L., Fand, I., Shen, S. Renn, O., and Meares, C. F., Comparative toxicity studies of yttrium-90 MX-DTPA and 2-IT-BAD conjugated monoclonal antibody. Cancer (Phila.), 73 (Suppl.): 1012-1022, 1994.
36. Li, M., and Meares, C. F., Synthesis, metal chelate stability studies, and enzyme digestion of a peptide-linked DOTA derivative and its corresponding radiolabeled immunoconjugates. Bioconjugate Chem. 4: 275-283, 1993.
37. Duke-Cohan, J. S., Morimoto, C., and Schlossman, S. F., Targeting of an activated T-cell subset using a bispecific antibody-toxin conjugate directed against CD4 and CD26. Blood, 82: 2224-2234, 1993.
38. Hawkins, G. A., McCabe, R. P., Kim, C. H., Subramanium, R., Bredehorst, R. McCullers, G. A., Vogel, C. W., Hanna, M. G., and Pomato, N., Delivery of radionuclides to pretargeted monoclonal antibodies using dihydrofolate reductase and methotrexate in an affinity system. Cancer Res. 53: 2368-2373, 1993.
39. Suresh, M. R., Cuello, A. C., and Milstein, C., Advantages of bispecific hybridomas in one-step immunocytochemistry and immunoassays: Proc. Natl. Acad. Sci. USA, 83: 7989-7993, 1986.
40. Bosslet, K., Stienstraesser, A. Hermentin, P., Kuhlmann, L. Bruynck, A., Magerstaedt, M. Seeman, G., Schwartz, A., and Sedlacek, H. H., Generation of bispecific monoclonal antibodies for two phase radioimmunotherapy. Br. J. Cancer, 63: 681-686, 1991.
41. 1 fragments. Science (Washington DC), 229: 81-83, 1985.
42. Frincke, J. M., Halpern, S. E., Chang, C. H., Ahlem, C., Anderson, L. D., Bartholomew, R. M., Poggenburg, J. K., Hagan, P. L., and Carlo, D. J., Radioimmunodetection (RID) approach using an 111 In hapten (H) monoclonal antibody (MoAb): studies in the nude mouse-human colon tumor model. J. Nucl. Med. 28: 711, 1987.
43. Stickney, D. R., Anderson, L. D., Slater, J. B., Ahlem, C. N., Kirk, G. A., Schweighardt, S. A., and Frincke, J. M., Bifunctional antibody: a binary radiopharmaceutical delivery system for imaging colorectal carcinoma. Cancer Res. 51: 6650-6655, 1991.
44. Matzku, S., Broecker, E. Bruggen, J., Dippold, W., and Tilgen, W., Modes of binding and internalization of monoclonal antibodies to human melanoma cell lines. Cancer Res. 46: 3848-3854, 1986.
45. Matzku, S., Tilgen, W. Kalthoff, H., Schmiegel, W., and Broecker, E., Dynamics of antibody transport and internalization. Int. J. Cancer, 2 (Suppl.): 11-14, 1988.
46. Hui, T. E., Fisher, D. R., Kuhn, J. A., Williams, L. E., Nourigat, C., Badger, C. C., Beatty, B. G., and Beatty, D. J., A mouse model for calculating cross-organ β dosed from yttrium-90-lableled immunoconjugates. Cancer (Phila.), 73 (Suppl.): 951-957, 1994.
47. 90Y-labeled immunoconjugate. Cancer (Phila.), 73 (Suppl.): 958-965, 1994.
48. Goodwin, D. A., Strategies for antibody targeting. Antibody Immunoconj. Radiopharm. 4: 427-434, 1991.
49. Virzi, F., Fritz, B. Ruskovski, M., Gionet, M. Misra, H., and Hnatowich, D. J., New indium-111 labeled biotin derivatives for improved immunotargeting. Int. J. Radiat. Appl. Instrum. Part B, 18: 719-726, 1991.
50. Goodwin, D. A., Meares, C. F., McCall, M. J., and McTigue, M., An avidin-biotin chelate system for imaging tumors. J. Nucl. Med. 28: 722, 1987.
51. Paganelli, G., Magnani, P. Zito, F., Villa, E. Sudati, F., Lopalco, L. Rossetti, C., Malcovati, M. Ciolerio, F., and Seccamani, E., Three-step monoclonal antibody tumor targeting in carcinoembryonic antigen-positive patients. Cancer Res. 51: 5960-5966, 1991.
52. Senter, P. D., Activation of prodrugs by antibody-enzyme conjugates: a new approach to cancer therapy. FASEB J. 4: 188-193, 1990.
53. Yuan, F., Baxter, L. T., and Jain, R. K., Pharmacokinetic analysis of two-step approaches using bifunctional and enzyme-conjugated antibodies. Cancer Res. 51: 3119-3130, 1991.
54. Strand, S. E., Norrgren, K., Garkavij, M. Lindgren, L., Nilsson, R. Sjogren, H. O., and Tennvall, J., A general extracorporeal immunoadsorption method to increase tumor-to-tissue ratio. Cancer (Phila.), 73 (Suppl.): 1033-1037, 1994.